Aardvark Pharma (AARD): Price/Earnings to Growth Multiple

Symbol and logo of brand Aardvark Pharma (AARD)

High patent barriers and strict FDA oversight provide Aardvark Therapeutics Inc (AARD) with protection of its market positions. The PEG fair value dynamics demonstrate the asset's resilience, where 0.00 serves as the final level mark. Business efficiency relies on outsourcing production to external partners, while a strong talent pool is retained through attractive options to develop promising pipelines.

AARD aardvarktherapeutics.com Price/Earnings to Growth Multiple (02/14/2025 - 11/17/2026)

Analytical breakdowns for Aardvark Therapeutics (AARD)

- share price and consensus valuation forecast:
- stock exchange capitalization data:
Fundamental company analysis:AARD - Aardvark Pharma
Signature product of aardvarktherapeutics.com

A conservative approach to analyzing Aardvark Therapeutics Inc (AARD) requires comparing market value with actual earnings expansion. This valuation-to-earnings growth ratio divides the P/E ratio by the income growth rate, where values below one signal an undervaluation of the potential for developing new molecules to treat rare diseases, turning this chart into an indicator of the biopharmaceutical business's investment attractiveness.

Competitors of Aardvark Therapeutics Inc

ASND (Ascendis) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio madrigalpharma.com MDGL|CORT - Price/Earnings to Growth Multiple|Rhythm Corp - PEG Multiple|Price to Earnings Adjusted for Growth Rate Akero Therapeutics Inc|MTSR (Metsera) - Price/Earnings to Growth Multiple|MLTX: Company Value to Earnings Growth Ratio|CRNX (Crinetics Corp) - PEG Multiple|PEG Multiple NewAmsterdam Pharma|PEG Multiple SLNO|Price/Earnings to Growth Ratio FOLD (Amicus Therapeutics Inc)|Price/Earnings to Growth Ratio 89bio.com ETNB|Agios Corp (AGIO) - Price to Earnings Adjusted for Growth Rate|GPCR - Price/Earnings to Growth Ratio|MDXG: Price/Earnings to Growth Ratio|RZLT: PEG Multiple|LXRX - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio MBX Corp|Price/Earnings to Growth Multiple Altimmune Corp (ALT)|Price/Earnings to Growth Ratio sagimet.com (SGMT)|Price/Earnings to Growth Multiple BioAge Labs, Inc. BIOA|PEG Multiple BMEA (Biomea Fusion)|Price to Net Income Growth Ratio quincetx.com|GUTS - Price/Earnings to Growth Ratio|vTv Therapeutics, Inc. - Company Value to Earnings Growth Ratio|ATPC: PEG Multiple|Pluri Inc (PLUR) - PEG Multiple|Price/Earnings to Growth Ratio Synlogic, Inc.|Price to Earnings Adjusted for Growth Rate Lipocine LPCN|Price/Earnings to Growth Ratio Matinas BioPharma Holdings Inc. (MTNB)|Price/Earnings to Growth Multiple Spruce Biosciences SPRB|Galecto Corp - Price/Earnings to Growth Multiple|carmellrx.com - Price/Earnings to Growth Ratio|LUMO - Price/Earnings to Growth Ratio|ONVO: Price/Earnings to Growth Ratio|Radius Health (RDUS) - Price/Earnings to Growth Ratio